Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HBM HoldingsHKSE:02142 -4.65%73 Gross Margin % is 93.16% as of Dec. 2025, which is 3% below its 10-year median of 95.65. GuruFocus rates HKSE:02142 with a GF Score™ of 73/100 and a GF Value™ of HK$7.03 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 733 Biotechnology companies, HBM Holdings ranks better than 92.09% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
HBM Holdings had a gross margin of 93.16% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
HBM Holdings Gross Margin % Related Terms
HBM Holdings Gross Margin % Historical Data
* Premium members only.
The historical data trend for HBM Holdings's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02142 vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, HBM Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HBM Holdings Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HBM Holdings's Gross Margin % distribution charts can be found below:
* The bar in red indicates where HBM Holdings's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
HBM Holdings (HKSE:02142) has a Gross Margin % of 93.16% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on HBM Holdings and its competitors. This is near median its historical median of 95.65. Over the past decade, HBM Holdings' Gross Margin % has ranged from 56.37 to 99.68. According to the industry distribution chart, HBM Holdings ranks #58 out of 733 companies in the Biotechnology industry, placing it in the top 7.9%.
Is HBM Holdings' Gross Margin % too high?
HBM Holdings' current Gross Margin % of 93.16% is near median its 10-year median of 95.65. Over the past 10 years, this metric has ranged from a low of 56.37 to a high of 99.68. The Biotechnology industry median Gross Margin % is 60.90. HBM Holdings' value of 93.16% is 53% above this industry median. Based on the distribution chart, HBM Holdings ranks #58 out of 733 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, HBM Holdings has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HBM Holdings' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HBM Holdings ranks #58 out of 733 companies for Gross Margin %. This places HBM Holdings in the top 8% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.90. HBM Holdings' value of 93.16% is 53% above this benchmark. Historically, HBM Holdings' own Gross Margin % has ranged from 56.37 to 99.68 over the past decade. While the company's 10-year median is 95.65 vs. the industry median of 60.90, HBM Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HBM Holdings's current Gross Margin % of 93.16% is 53% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on HBM Holdings and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HBM Holdings's current Gross Margin % is 93.16%, which is near median its own 10-year median of 95.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HBM Holdings stock overvalued right now?
Based on GuruFocus' analysis, HBM Holdings (HKSE:02142) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$7.03, compared to a current price of HK$11.69 — trading 66.3% above its estimated fair value. The current Gross Margin % is 93.16%, which is near median its 10-year median of 95.65 and 53% above the Biotechnology industry median of 60.90. HBM Holdings' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For HBM Holdings (HKSE:02142), the current Gross Margin % is 93.16% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HBM Holdings (HKSE:02142) Overvalued in 2026?
Based on GuruFocus' analysis, HBM Holdings stock appears to be overvalued.
The current stock price of HK$11.69 is trading 66.3% above its estimated GF Value™ of HK$7.03.
GuruFocus considers HBM Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:02142:
Gross Margin %: 93.16% (near median its 10-year median of 95.65)
GF Value™: HK$7.03 vs. price of HK$11.69 (66.3% above fair value)
Industry Position: 53% above the Biotechnology median (#58 of 733)
No single metric tells the full story. See the HKSE:02142 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the Europe.
73GF Score
Get the complete analysis for HKSE:02142
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02142 has been successfully added to your 
